Literature DB >> 23659668

What liver transplant outcomes can be expected in the uninsured who become insured via the Affordable Care Act?

L N Glueckert1, D Redden, M A Thompson, A Haque, S H Gray, J Locke, D E Eckhoff, M Fouad, D A DuBay.   

Abstract

Our study objective is to measure the survival impact of insurance status following liver transplantation in a cohort of uninsured "charity care" patients. These patients are analogous to the population who will gain insurance via the Affordable Care Act. We hypothesize there will be reduced survival in charity care compared to other insurance strata. We conducted a retrospective study of 898 liver transplants from 2000 to 2010. Insurance cohorts were classified as private (n = 640), public (n = 233) and charity care (n = 23). The 1, 3 and 5-year survival was 92%, 88% and 83% in private insurance, 89%, 80% and 73% in public insurance and 83%, 72% and 51% in charity care. Compared to private insurance, multivariable regression analyses demonstrated charity care (HR 3.11, CI 1.41-6.86) and public insurance (HR 1.58, CI 1.06-2.34) had a higher 5-year mortality hazard ratio. In contrast, other measures of socioeconomic status were not significantly associated with increased mortality. The charity care cohort demonstrated the highest incidence of acute rejection and missed clinic appointments. These data suggest factors other than demographic and socioeconomic may be associated with increased mortality. Further investigations are necessary to determine causative predictors of increased mortality in liver transplant patients without private insurance. © Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2013        PMID: 23659668      PMCID: PMC3671495          DOI: 10.1111/ajt.12244

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  18 in total

1.  Psychological characteristics of candidates for liver transplantation: differences according to history of substance abuse and UNOS listing. United Network for Organ Sharing.

Authors:  C S Stilley; D J Miller; T Gayowski; I R Marino
Journal:  J Clin Psychol       Date:  1999-10

2.  Insurance and education predict long-term survival after orthotopic heart transplantation in the United States.

Authors:  Jeremiah G Allen; Eric S Weiss; George J Arnaoutakis; Stuart D Russell; William A Baumgartner; Ashish S Shah; John V Conte
Journal:  J Heart Lung Transplant       Date:  2011-10-01       Impact factor: 10.247

3.  Insurance status is an independent predictor of long-term survival after lung transplantation in the United States.

Authors:  Jeremiah G Allen; George J Arnaoutakis; Jonathan B Orens; John McDyer; John V Conte; Ashish S Shah; Christian A Merlo
Journal:  J Heart Lung Transplant       Date:  2011-01       Impact factor: 10.247

4.  Race, socioeconomic status, and breast cancer treatment and survival.

Authors:  Cathy J Bradley; Charles W Given; Caralee Roberts
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

5.  Psychiatric and psychosocial predictors of medical outcome after liver transplantation: a prospective, single-center study.

Authors:  D Telles-Correia; A Barbosa; I Mega; E Barroso; E Monteiro
Journal:  Transplant Proc       Date:  2011 Jan-Feb       Impact factor: 1.066

6.  Orthotopic liver transplantation in a multiethnic population: role of spatial accessibility.

Authors:  N Kemmer; A Alsina; G W Neff
Journal:  Transplant Proc       Date:  2011-12       Impact factor: 1.066

7.  Morbidity and mortality of colorectal carcinoma surgery differs by insurance status.

Authors:  Rachel Rapaport Kelz; Phyllis A Gimotty; Daniel Polsky; Sandra Norman; Douglas Fraker; Angela DeMichele
Journal:  Cancer       Date:  2004-11-15       Impact factor: 6.860

8.  Outcome of liver transplantation in adult recipients: influence of neighborhood income, education, and insurance.

Authors:  Hwan Young Yoo; Paul J Thuluvath
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

9.  Sociodemographic differences in early access to liver transplantation services.

Authors:  C L Bryce; D C Angus; R M Arnold; C-C H Chang; M H Farrell; C Manzarbeitia; I R Marino; M S Roberts
Journal:  Am J Transplant       Date:  2009-07-23       Impact factor: 8.086

10.  Insurance status, comorbidity level, and survival among colorectal cancer patients age 18 to 64 years in the National Cancer Data Base from 2003 to 2005.

Authors:  Anthony S Robbins; Alexandre L Pavluck; Stacey A Fedewa; Amy Y Chen; Elizabeth M Ward
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

View more
  4 in total

1.  Change in Health Insurance Coverage After Liver Transplantation Can Be Associated with Worse Outcomes.

Authors:  Clifford Akateh; Dmitry Tumin; Eliza W Beal; Khalid Mumtaz; Joseph D Tobias; Don Hayes; Sylvester M Black
Journal:  Dig Dis Sci       Date:  2018-03-24       Impact factor: 3.199

2.  Insurance Type and Solid Organ Transplantation Outcomes: A Historical Perspective on How Medicaid Expansion Might Impact Transplantation Outcomes.

Authors:  Derek A DuBay; Paul A MacLennan; Rhiannon D Reed; Brittany A Shelton; David T Redden; Mona Fouad; Michelle Y Martin; Stephen H Gray; Jared A White; Devin E Eckhoff; Jayme E Locke
Journal:  J Am Coll Surg       Date:  2016-07-25       Impact factor: 6.113

3.  Cancer-specific outcomes among young adults without health insurance.

Authors:  Ayal A Aizer; Benjamin Falit; Mallika L Mendu; Ming-Hui Chen; Toni K Choueiri; Karen E Hoffman; Jim C Hu; Neil E Martin; Quoc-Dien Trinh; Brian M Alexander; Paul L Nguyen
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

4.  Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients.

Authors:  Meredith S Shiels; Glenn Copeland; Marc T Goodman; Janna Harrell; Charles F Lynch; Karen Pawlish; Ruth M Pfeiffer; Eric A Engels
Journal:  Cancer       Date:  2015-03-04       Impact factor: 6.921

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.